glp-1 treatments How medications are transforming diabetes and weight loss treatment Understanding GLP-1 medications

Description

In Phase 3 SURMOUNT trials, Retatrutide achieved unprecedented 24.2% mean weight loss at the 12mg dose over 48 weeks, with 91% of participants achieving 15% body weight reduction

[DOI] [PubMed] [Google Scholar] 455.Jones B., Buenaventura T., Kanda N., Chabosseau P., Owen B.M., Scott R

Additionally, if gastrointestinal side effects from semaglutide (nausea, vomiting) interfere with the ability to take levothyroxine consistently, medical guidance is needed to maintain thyroid control

After 7 months, the offering is generating $100M in run-rate revenue across 100k incremental subscribers

References: GLP-1 Single, Dual, and Triple Receptor Agonists The Lancet eClinicalMedicine 2024 GLP-1 Receptor Agonists State of the Art PMC Emerging Frontiers in GLP-1 Therapeutics 2025 PMC SGLT2 Inhibitors Jardiance & Farxiga: The Diabetes Drug That Protects Your Heart and Kidneys Here is something remarkable